Follicular Lymphoma
Conference Coverage
Genetic screening for CLL premature, speaker says
Photo courtesy of the National Institute of General Medical Science NEW YORK—Research has shown that family history is a strong risk factor for...
News
COMP recommends orphan designation for CMV-CTLs
The European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) is recommending orphan designation for a cytomegalovirus-specific...
News
Cancer report details progress, predicts problems
Photo by Rhoda Baer A new report highlights recent advances made in the fight against cancer but suggests the burden of cancer in the US is still...
News
Optimizing CAR T-cell therapy in NHL
Photo from Fred Hutchinson Cancer Research Center Results from a phase 1 study have provided insights that may help researchers optimize treatment...
News
Metabolic tumor volume predicts outcome in follicular lymphoma
Key clinical point: At diagnosis, the total metabolic tumor volume of follicular lymphoma predicts treatment response and patient outcome. Major...
News
New treatment option for relapsed/refractory NHL
Results of the phase 3 GADOLIN trial have revealed a new treatment option for patients with relapsed/refractory non-Hodgkin lymphoma (NHL),...
News
Drug no longer in development for DLBCL, other cancers
ProNAi Therapeutics recently announced its decision to stop development of PNT2258, a drug designed to treat cancers characterized by...
News
CAR T-cell therapy granted orphan designation
Photo courtesy of NIAID The US Food and Drug Administration (FDA) has granted orphan drug designation for a CD4-directed chimeric antigen receptor...
News
Lenalidomide maintenance doesn’t improve OS in DLBCL
Photo courtesy of Celgene Initial results from the phase 3 REMARC study suggest that lenalidomide (Revlimid) maintenance does not prolong overall...
News
Combo doesn’t improve PFS in DLBCL
Results of a phase 3 study suggest that obinutuzumab may not confer a benefit over standard therapy in patients with previously untreated diffuse...
News
Drug’s benefits outweigh risks, PRAC says
Photo courtesy of Gilead Sciences, Inc. The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed its...